Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.
Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.